Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase …

KB Gordon, P Foley, JG Krueger, A Pinter, K Reich… - The Lancet, 2021 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …
被引用次数：217 相关文章

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase …

KB Gordon, P Foley, JG Krueger, A Pinter, K Reich… - 2021 - pubmed.ncbi.nlm.nih.gov
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase …

KB Gordon, P Foley, JG Krueger, A Pinter, K Reich… - The Lancet, 2021 - Elsevier
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase …

KB Gordon, P Foley, JG Krueger, A Pinter… - Lancet (London …, 2021 - europepmc.org
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …